New technologies for the enhancement of skeletal repair

被引:83
作者
Axelrad, T. William [1 ]
Kakar, Sanjeev [1 ]
Einhorn, Thomas A. [1 ]
机构
[1] Boston Univ, Med Ctr, Dept Orthopaed Surg, Boston, MA 02118 USA
来源
INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED | 2007年 / 38卷
关键词
fracture repair; bone morphogenetic protein; parathyroid hormone; HMG-CoA reductase inhibitors; nonunion; EP2 receptor agonist; EP4 receptor agonist; transforming growth factor B; platelet-derived growth factor; TP508; vascular endothelial growth factor; gene therapy;
D O I
10.1016/j.injury.2007.02.010
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Although fracture heating is a well-optimized biological process that leads to heating, approximately 10-20% of fractures result in impaired or delayed heating and these fractures may benefit from the use of biotechnologies to enhance skeletal repair. Peptide signaling molecules such as the bone morphogenetic proteins have been shown to stimulate the heating of fresh fractures, nonunions, and spinal fusions and side effects from their use appear to be minimal. Other growth factors currently being studied for local application include growth and differentiation factor-5 (GDF-5), vascular endothelial growth factor (VEGF), transforming growth factor beta (TGF beta), and platelet-derived growth factor (PDGF). Molecules such as prostaglandin E receptor agonists and the thrombin-related peptide, TP508, have shown promise in animal models of fracture repair. Gene therapy using various growth factors or combinations of factors might also aid in fracture repair, particularly as new methods for delivery that do not require viral vectors are developed. Systemic therapy with agents such as parathyroid hormone (PTH), growth hormone (GH), and the HMG-CoA reductase inhibitors are also under investigation. As these and other technologies are shown to be safe and effective, their use will become a part of the standard of care in managing skeletal injuries.
引用
收藏
页码:S49 / S62
页数:14
相关论文
共 141 条
[1]   Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34) [J].
Alkhiary, YM ;
Gerstenfeld, LC ;
Krall, E ;
Westmore, M ;
Sato, M ;
Mitlak, BH ;
Einhorn, TA .
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 2005, 87A (04) :731-741
[2]   Intermittent parathyroid hormone (1-34) treatment increases callus formation and mechanical strength of healing rat fractures [J].
Andreassen, TT ;
Ejersted, C ;
Oxlund, H .
JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 (06) :960-968
[3]  
ANDREW JG, 1995, BONE, V16, P455
[4]   Autologous platelets as a source of proteins for healing and tissue regeneration [J].
Anitua, E ;
Andia, I ;
Ardanza, B ;
Nurden, P ;
Nurden, AT .
THROMBOSIS AND HAEMOSTASIS, 2004, 91 (01) :4-15
[5]   Platelet-activating factor (PAF) induces activation of matrix metalloproteinase 2 activity and vascular endothelial cell invasion and migration [J].
Axelrad, TW ;
Deo, DD ;
Ottino, P ;
Van Kirk, J ;
Bazan, NG ;
Bazan, HEP ;
Hunt, JD .
FASEB JOURNAL, 2004, 18 (01) :568-+
[6]   INCREASED MECHANICAL STRENGTH OF HEALING RAT TIBIAL FRACTURES TREATED WITH BIOSYNTHETIC HUMAN GROWTH-HORMONE [J].
BAK, B ;
JORGENSEN, PH ;
ANDREASSEN, TT .
BONE, 1990, 11 (04) :233-239
[7]  
BAK B, 1991, CLIN ORTHOP RELAT R, P295
[8]   Thrombin causes vascular endothelial growth factor expression in vascular smooth muscle cells -: Role of reactive oxygen species [J].
Bassus, S ;
Herkert, O ;
Kronemann, N ;
Görlach, A ;
Bremerich, D ;
Kirchmaier, CM ;
Busse, R ;
Schini-Kerth, VB .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2001, 21 (09) :1550-1555
[9]   Direct percutaneous gene delivery to enhance healing of segmental bone defects [J].
Betz, OB ;
Betz, VM ;
Nazarian, A ;
Pilapil, CG ;
Vrahas, MS ;
Bouxsein, ML ;
Gerstenfeld, LC ;
Einhorn, TA ;
Evans, CH .
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 2006, 88A (02) :355-365
[10]  
Bong MR, 2005, BULL HOSP JT DIS, V63, P20